Acute Myelocytic Leukemia Clinical Trial
Official title:
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia
This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting CD123 in the treatment of Acute Myelocytic Leukemia. A total of 15 patients are planned to be enrolled following up one year.
Status | Recruiting |
Enrollment | 15 |
Est. completion date | June 6, 2021 |
Est. primary completion date | November 6, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Subjects with acute myeloid leukemia who voluntarily signed informed consent and met the following criteria: 1. Diagnosed as recurrent or refractory acute myeloid leukemia 2. Tumor cells confirmed CD123 positive by Flow cytometry (FCM) or immunohistochemical detection, and CD123 positive rate >80% 3. Age = 2 years old, and <65 years old 4. Estimated survival time is longer than 3 months from the date of signing the informed consent form 5. KPS = 80 points 6. Important organs function need to meet the following conditions: 1) EF>50%, and there is no obvious abnormality in ECG; 2) SpO2=90%; 3)Cr=2.5ULN; 4)ALT and AST=4ULN, TBil=50µmol/L 7. Subjects with a pregnancy plan must agree to take contraception before the enrollment study and after the study lasts for six months; if the subject is pregnant or suspects of pregnancy, the investigator should be notified immediately 8. Need to stop chemotherapy for at least 2 weeks before collecting the blood to manufacture CAR-T cells. 9. For allogeneic hematopoietic stem cell transplantation subjects, it is necessary to stop the immunosuppressant against GVHD for at least 2 weeks before collecting autologous blood preparation, and if the donor is preparing blood, it is of no influence; 10. If the subject has a history of central nervous system (CNS) leukemia, the tumor cells in the cerebrospinal fluid need to be cleared and the white blood cell count <5 * 10^6 / L ,then can proceed lymphodepletion 11. Subjects who participate in other studies must withdraw other studies for 2 weeks before they can be enrolled. Exclusion Criteria: 1. Combine other diseases not effectively controlled, including but not limited to persistent or poorly controlled infections, symptomatic congestive heart failure, unstable angina, arrhythmia, poorly controlled lung disease or mental illness 2. There are other active malignant tumors 3. Combined serious infection and can not be effectively controlled 4. Active hepatitis (HBV DNA or hepatitis C virus ribonucleic acid [HCVRNA] detection positive) 5. Human immunodeficiency virus (HIV) infection or syphilis infection 6. Have a history of severe allergies in biological products (including antibiotics) 7. One month after discontinuation of immunosuppressants, allogeneic hematopoietic stem cell transplantation patients still have acute graft versus host response (GvHD) 8. Female subjects are pregnant or lactating 9. Systemic administration of glucocorticoids within one week prior to CAR-T treatment 10. In the past, there was a prolonged QT interval or severe heart disease. 11. Active autoimmune diseases requiring systemic immunosuppressive therapy 12. The investigator believes that it may increase the risk of the subject or interfere with the study results. Exit criteria: 1. The subjects request to withdraw from the study before CAR-T infusion 2. The subjects seriously violate the protocol 3. Before CAR-T infusion, the following indicators are still abnormal after treatment: 1) EF>50%, and there is no obvious abnormality in ECG 2) SpO2=90% 3)Cr=2.5ULN(the upper limit of normal ) 4) ALT and AST = 4ULN, TBil = 50µmol / L 4.Not enough T cells for manufacture standard CAR-T cells 5. Other serious adverse events occurred |
Country | Name | City | State |
---|---|---|---|
China | Hebei Yanda Ludaopei Hospital | Langfang | Hebei |
Lead Sponsor | Collaborator |
---|---|
Hebei Senlang Biotechnology Inc., Ltd. | Hebei Yanda Ludaopei Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tumor load | Tumor load will be quantified with radiology, bone marrow and/or blood samples dependent on diagnosis. | Up to 12 months | |
Secondary | CAR-T cell persistence | CAR-T cell persistence will be quantified with flow cytometry and qPCR; Percentage of CART cells in BM and copies of car per ug DNA | Up to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02244658 -
Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia
|
Phase 3 | |
Completed |
NCT01462578 -
Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)
|
Phase 2 | |
Completed |
NCT01188798 -
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
|
Phase 3 | |
Recruiting |
NCT06105658 -
Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML
|
Phase 2 | |
Completed |
NCT00854646 -
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
|
Phase 1 | |
Completed |
NCT00152139 -
Stem Cell Transplantation for Patients With Hematologic Malignancies
|
Phase 3 | |
Completed |
NCT00061581 -
Experimental Bone Marrow Transplant Protocol
|
Phase 2 | |
Completed |
NCT01167166 -
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
|
Phase 1/Phase 2 | |
Completed |
NCT01474681 -
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
|
Phase 1/Phase 2 | |
Terminated |
NCT02255162 -
Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML
|
Phase 1 | |
Active, not recruiting |
NCT01809392 -
Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
|
Phase 2/Phase 3 | |
Recruiting |
NCT00155844 -
Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier"
|
N/A | |
Terminated |
NCT01621477 -
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
|
Phase 2 | |
Completed |
NCT00559091 -
A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia
|
Phase 2 | |
Completed |
NCT00015587 -
Molecular Epidemiology of Childhood Leukemia (Aka The California Childhood Leukemia Study)
|
N/A |